Skip to main content

Table 1 Baseline cohort characteristics

From: Lipid parameters, adipose tissue distribution and prognosis prediction in chronic kidney Disease patients

Variables

N(%)/Mean(SD)/Median[25th,75th]

Variables

N(%)/Mean(SD)/Median[25th,75th]

Age

 

58.8 [48.7, 67.2]

Medication

 

Gender

Male

429(54.03)

ACEI/ARB

336(42.32)

Female

365(45.97)

Other antihypertensive drugs

432(54.41)

Marital status

Unmarried

40(5.04)

Hypoglycemic agents

171(21.54)

Married

737(94.85)

Urate-lowering drugs

404(50.89)

Alcohol Consumption

No

779(98.11)

Lipid-lowering drugs

272(34.36)

Yes

15(1.89)

Folic acid tablets

86(10.83)

Current Smoker

No

725(91.31)

Polysaccharide iron

122(15.37)

Yes

69(8.69)

EPO

133(16.75)

Education

Elementary school

118(14.90)

Hb, g/L

119.64(21.75)

 

Junior high school

229(28.91)

TCO2, mmol/L

22.90 [20.78, 25.00]

 

High school

257(32.45)

UA, µmmol/L

427.00 [370.75, 501.75]

 

College degree or above

188(23.74)

Urea, mmol/L

10.87 [7.92, 15.75]

Without self-care capacity

Yes

52(6.55)

ALB, g/L

43.60 [40.28, 46.10]

No

742(93.45)

eGFR, ml/min/1.73 m2

33.7 [17.6, 47.8]

Protopathy

Primary Glomerulonephritides

270(34.01)

K+, mmol/L

4.48 [4.18, 4.83]

Hypertensive Renal Disease

44(5.54)

Na+, mmol/L

141.00 [139.00, 142.00]

Diabetic nephropathy

110(13.85)

Ca2+, mmol/L

2.33 [2.25, 2.42]

Others

118(14.86)

P, mmol/L

1.28 [1.12, 1.44]

Unknown

252(31.74)

UPCR, mg/g

0.87[0.27,2.03]

Comorbidity

 

TG, mmol/L

1.49 [1.10, 2.18]

Hypertension management

 

TC, mmol/L

4.79 [4.00, 5.57]

 Hypertension with normal BP

164(20.66)

HDL-C, mmol/L

1.26 [1.00, 1.52]

 Hypertension with abnormal BP

396(49.87)

LDL-C, mmol/L

3.03 [2.30, 3.73]

 Hypertension with without regular assessment

95(11.97)

TSKF, cm

1.40 [1.00, 1.90]

 Non-hypertension

139(17.51)

MUAC, cm

27.00 [25.40, 29.00]

Glu management

 

BMI, kg/m2

22.80 [20.60, 25.03]

 Diabetes with normal Glu

142(17.89)

BFM, kg

15.45 [11.35, 19.90]

 Diabetes with abnormal Glu

117(14.74)

FMI, %

5.90 [4.30, 7.50]

 Diabetes without regular assessment

75(9.45)

PBF, %

26.19(8.38)

 Non-diabetes

460(57.94)

VFA, cm2

68.70 [51.87, 91.63]

UA management

 

TBW, kg/L

32.65 [27.80, 37.51]

 Hyperuricemia with normal uric acid

198(24.94)

ICW, kg/L

20.00 [16.90, 22.90]

 Hyperuricemia with anormal uric acid

387(48.74)

ECW, kg/L

12.65 [10.90, 14.60]

 Non-hyperuricemia

206(25.95)

FFM, kg

44.20 [37.90, 51.00]

With history of cardiovascular disease

161(20.28)

FFMI, %

16.83(2.05)

  1. Note:Primary Glomerulonephritides included chronic nephritis, nephropathy syndrome and IgA nephropathy.Other secondary nephrosis included systemic lupus erythematosus nephritis, Henoch-Schonlein purpura,Hepatitis B virus-associated nephritis and obstructive nephropathy, etc. Blood Pressure, BP; Angiotensin converting enzyme, ACE; Angiotensin receptor blocker, ARB; Uric acid, UA; Erythropoietin, EPO; Hemoglobin, Hb; Triglyceride, TG; total cholesterol, TC; high-density lipoprotein cholesterol,HDL-C; low-density lipoprotein cholesterol, LDL-C; Total carbon dioxide, TCO2; albumin, ALB; Urine protein-to-creatinine, UPCR; Body Mass Index, BMI; triceps skinfold thickness, TSKF; mid-arm circumference, MUAC; Body Fat Mass, BFM; Fat Mass Index, FMI; Percent Body Fat, PBF; Visceral Fat Area, VFA; Total Body Water, TBW; Intracellular Water, ICW; Extracellular Water, ECW; Fat Free Mass, FFM; Fat Free Mass Index, FFMI.
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X